Lenalidomide combined with decitabine for acute myeloid leukemia with germline/somatic DDX41 mutation:a case report and literatures review
10.3781/j.issn.1000-7431.2023.2110-0793
- VernacularTitle:来那度胺联合地西他滨治疗伴DDX41胚系/体细胞突变急性髓系白血病:1例报告及文献复习
- Author:
Renjun BAO
1
;
Yuhua FU
;
Yonghua YAO
;
Li CHEN
;
Ti ZHANG
;
Chenglin YE
Author Information
1. 上海市杨浦区市东医院(上海理工大学附属市东医院)血液科,上海 200438
- Keywords:
Lenalidomide;
Decitabine;
DDX41;
Acute myeloid leukemia;
Germline DDX41 mutation;
Somatic DDX41 mutation
- From:
Tumor
2023;43(1):53-60
- CountryChina
- Language:Chinese
-
Abstract:
Objective:The paper seeks to explore the characteristics of myeloid tumors with genetic DDX41 gene mutations,especially focusing on the understanding and treatment of acute myeloid leukemia with germline/somatic DDX41 mutation. Methods:One AML patient with germline/somatic DDX41 mutation who was diagnosed by using morphology,immunology,cytogenetics and molecular biology in Shanghai Shidong Hospital was retrospectively analyzed,and the patient was treated with lenalidomide combined with decitabine,and the literatures were reviewed. Results:The patient obtained complete remission after the therapy and there were no relevant adverse reactions to the treatment. Conclusion:The DDX41 gene mutations have effects on the prognosis and treatment of myeloid malignancies,and lenalidomide combined with decitabine is effective in acute myeloid leukemia with germline/somatic DDX41 mutation.The germline mutation status should be identified and confirmed early.
